GSK PLC Sponsored ADR $GSK Stock: Prime Capital Investment Advisors LLC Lowers Holdings

Prime Capital Investment Advisors LLC trimmed its holdings in shares of GSK PLC Sponsored ADR (NYSE:GSK) by 47.2% during the third quarter, Holdings Channel reports. The fund owned 22,296 shares of the pharmaceutical company’s stock after selling 19,931 shares during the quarter. Prime Capital Investment Advisors LLC’s holdings in GSK were worth $1,074,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of GSK. Security National Bank of SO Dak purchased a new position in GSK in the second quarter valued at about $38,000. Trust Co. of Vermont acquired a new stake in GSK during the 2nd quarter valued at approximately $54,000. Philadelphia Investment Partners LLC acquired a new stake in GSK during the 2nd quarter valued at approximately $70,000. Ancora Advisors LLC purchased a new stake in GSK during the 2nd quarter worth approximately $71,000. Finally, Bogart Wealth LLC increased its holdings in GSK by 15.3% during the 1st quarter. Bogart Wealth LLC now owns 1,508 shares of the pharmaceutical company’s stock worth $83,000 after purchasing an additional 200 shares during the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Stock Down 0.9%

NYSE:GSK opened at $50.74 on Friday. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.52 and a current ratio of 0.82. The company has a market capitalization of $102.64 billion, a price-to-earnings ratio of 15.87, a price-to-earnings-growth ratio of 2.30 and a beta of 0.33. GSK PLC Sponsored ADR has a one year low of $42.85 and a one year high of $61.69. The stock has a 50-day simple moving average of $49.59 and a 200 day simple moving average of $51.45.

GSK (NYSE:GSK) last announced its quarterly earnings data on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.09. GSK had a return on equity of 43.23% and a net margin of 14.56%. The firm had revenue of $11.14 billion for the quarter, compared to analysts’ expectations of $11.02 billion. During the same quarter in the prior year, the firm posted $0.47 earnings per share. GSK’s revenue for the quarter was up 5.3% compared to the same quarter last year. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. Sell-side analysts predict that GSK PLC Sponsored ADR will post 4.78 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, October 8th. Stockholders of record on Friday, August 14th were issued a $0.4515 dividend. This is a positive change from GSK’s previous quarterly dividend of $0.44. The ex-dividend date was Friday, August 14th. This represents a $1.81 dividend on an annualized basis and a dividend yield of 3.6%. GSK’s dividend payout ratio (DPR) is presently 55.31%.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Weiss Ratings lowered GSK from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, July 29th. Morgan Stanley reissued an “underweight” rating on shares of GSK in a research report on Tuesday, August 25th. Berenberg Bank restated a “buy” rating on shares of GSK in a research note on Tuesday, October 6th. Wolfe Research began coverage on shares of GSK in a report on Friday, October 9th. They issued an “outperform” rating and a $70.00 price target on the stock. Finally, Deutsche Bank Aktiengesellschaft reiterated a “neutral” rating on shares of GSK in a research note on Tuesday, September 29th. Four research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $55.33.

About GSK

GSK plc, formerly GlaxoSmithKline, is a global biopharmaceutical company headquartered in Brentford, England. The company focuses on researching, developing and commercializing medicines and vaccines designed to prevent and treat infectious diseases, respiratory conditions, immune-related disorders and certain cancers.

Its vaccine portfolio includes products such as Shingrix for shingles, Arexvy for respiratory syncytial virus (RSV) in older adults, and vaccines targeting meningitis, influenza and other infectious diseases.